Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJMI.L Regulatory News (JMI)

  • There is currently no data for JMI

Results analysis from Kepler Trust Intelligence

13 Oct 2021 16:19

RNS Number : 9968O
JPMorgan UK Smaller Cos IT PLC
13 October 2021
 

JPMorgan UK Smaller Companies (JMI)

13/10/2021

Results analysis from Kepler Trust Intelligence

JPMorgan UK Smaller Companies (JMI), formerly JPMorgan Smaller Companies, has reported strong results for the year ending 31 July 2021. Outstanding returns from UK smaller companies has been accompanied by substantial outperformance.

Over the period the trust benefitted from positions in defensive names robust to the effects of the pandemic as well as buying into discounted cyclical names that suffered from the initial impact of the pandemic but would emerge stronger in the recovery as weaker competitors fell by the wayside.

Kepler view

The recently renamed JPMorgan UK Smaller Companies (JMI) has posted a year of excellent results. This has contributed to an outstanding long term track record of outperforming their benchmark and peers; the trust is ranked 3/14 within its peer group over the last five years for NAV total returns (as at 11/10/2021, source: JPMorgan Cazenove).

 

This success has been based on the experience of the long-standing managers Georgina Brittain and Katen Patel (tenures beginning in 1998 and 2014 respectively) following a well-established process combining a quantitative system balancing quality, valuation and momentum factors with bottom-up fundamental analysis. We note that balancing the portfolio between 'growth' (higher quality, premium) stocks and more cyclical, less expensive 'value' stocks has helped the portfolio to navigate the extreme style rotations that have occurred in the last year.

 

For an investor with a bullish outlook on UK smaller companies as an asset class, we think JMI is a way of gaining exposure that balances the potential for outperformance without making a binary stylistic bet on 'growth' versus 'value'. If the ongoing rally in UK smaller companies is led by cheaper, value stocks driven by broad economic recovery or if the nascent tech, growth orientated sectors begin to emerge as winners then JMI should benefit either way due to their balanced approach.

 

 

CLICK HERE TO READ THE FULL REPORT

Visit http://www.trustintelligence.co.uk/investor for more high quality independent investment trust research.

 

Important information

This report has been issued by Kepler Partners LLP. The analyst who has prepared this report is aware that Kepler Partners LLP has a relationship with the company covered in this report and/or a conflict of interest which may impair the objectivity of the research.

Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise and you may get back less than you invested when you decide to sell your investments. It is strongly recommended that if you are a private investor independent financial advice should be taken before making any investment or financial decision.

Kepler Partners is not authorised to make recommendations to retail clients. This report has been issued by Kepler Partners LLP, is based on factual information only, is solely for information purposes only and any views contained in it must not be construed as investment or tax advice or a recommendation to buy, sell or take any action in relation to any investment.

The information provided on this website is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Kepler Partners LLP to any registration requirement within such jurisdiction or country. In particular, this website is exclusively for non-US Persons. Persons who access this information are required to inform themselves and to comply with any such restrictions.

The information contained in this website is not intended to constitute, and should not be construed as, investment advice. No representation or warranty, express or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise. Any views and opinions, whilst given in good faith, are subject to change without notice.

This is not an official confirmation of terms and is not a recommendation, offer or solicitation to buy or sell or take any action in relation to any investment mentioned herein. Any prices or quotations contained herein are indicative only.

Kepler Partners LLP (including its partners, employees and representatives) or a connected person may have positions in or options on the securities detailed in this report, and may buy, sell or offer to purchase or sell such securities from time to time, but will at all times be subject to restrictions imposed by the firm's internal rules. A copy of the firm's Conflict of Interest policy is available on request.

PLEASE SEE ALSO OUR TERMS AND CONDITIONS

Kepler Partners LLP is authorised and regulated by the Financial Conduct Authority (FRN 480590), registered in England and Wales at 70 Conduit Street, London W1S 2GF with registered number OC334771.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABUBDGRBBDGBX
Date   Source Headline
31st Jul 202312:26 pmRNSGearing Announcement
31st Jul 202311:52 amRNSNet Asset Value(s)
28th Jul 202311:19 amRNSNet Asset Value(s)
27th Jul 202310:29 amRNSNet Asset Value(s)
26th Jul 202310:39 amRNSNet Asset Value(s)
25th Jul 202310:52 amRNSNet Asset Value(s)
24th Jul 202312:23 pmRNSGearing Announcement
24th Jul 202310:36 amRNSNet Asset Value(s)
21st Jul 202310:34 amRNSNet Asset Value(s)
20th Jul 202311:06 amRNSNet Asset Value(s)
19th Jul 202311:08 amRNSNet Asset Value(s)
18th Jul 202310:55 amRNSNet Asset Value(s)
17th Jul 202312:06 pmRNSGearing Announcement
17th Jul 202311:01 amRNSNet Asset Value(s)
14th Jul 20233:09 pmRNSTen Largest Investments
14th Jul 202310:58 amRNSNet Asset Value(s)
13th Jul 202311:09 amRNSNet Asset Value(s)
12th Jul 202311:31 amRNSNet Asset Value(s)
11th Jul 202310:39 amRNSNet Asset Value(s)
10th Jul 20231:00 pmRNSGearing Announcement
10th Jul 202311:27 amRNSNet Asset Value(s)
7th Jul 202311:47 amRNSNet Asset Value(s)
6th Jul 202310:51 amRNSNet Asset Value(s)
5th Jul 202310:27 amRNSNet Asset Value(s)
4th Jul 202311:30 amRNSNet Asset Value(s)
3rd Jul 20231:09 pmRNSGearing announcement
3rd Jul 202312:24 pmRNSNet Asset Value(s)
30th Jun 202311:40 amRNSNet Asset Value(s)
29th Jun 202311:29 amRNSNet Asset Value(s)
29th Jun 20237:00 amRNSWebinar hosted by Capital Access Group and Doceo
28th Jun 202310:38 amRNSNet Asset Value(s)
27th Jun 202310:33 amRNSNet Asset Value(s)
26th Jun 202312:56 pmRNSGearing announcement
26th Jun 202311:18 amRNSNet Asset Value(s)
23rd Jun 202311:04 amRNSNet Asset Value(s)
22nd Jun 202311:09 amRNSNet Asset Value(s)
21st Jun 202311:35 amRNSNet Asset Value(s)
20th Jun 202311:10 amRNSNet Asset Value(s)
19th Jun 20231:06 pmRNSGearing announcement
19th Jun 202311:15 amRNSNet Asset Value(s)
16th Jun 202311:24 amRNSNet Asset Value(s)
16th Jun 202310:51 amRNSTen Largest Investments
15th Jun 202311:03 amRNSNet Asset Value(s)
14th Jun 202310:44 amRNSNet Asset Value(s)
13th Jun 202311:10 amRNSNet Asset Value(s)
12th Jun 202312:15 pmRNSGearing announcement
12th Jun 202311:12 amRNSNet Asset Value(s)
9th Jun 202311:09 amRNSNet Asset Value(s)
8th Jun 202311:09 amRNSNet Asset Value(s)
7th Jun 202312:19 pmRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.